S&P 500   4,145.19
DOW   32,803.47
QQQ   321.75
China July exports rise, with trade surplus at record-high
Demand for grocery delivery cools as food costs rise
Musk says Twitter deal could move ahead with 'bot' info
Shift in war's front seen as ships cleared to leave Ukraine
Dems' climate, energy, tax bill clears initial Senate hurdle
Transit woes mount for Boston's beleaguered subway riders
Dems push Biden climate, health priorities toward Senate OK
pixel
S&P 500   4,145.19
DOW   32,803.47
QQQ   321.75
China July exports rise, with trade surplus at record-high
Demand for grocery delivery cools as food costs rise
Musk says Twitter deal could move ahead with 'bot' info
Shift in war's front seen as ships cleared to leave Ukraine
Dems' climate, energy, tax bill clears initial Senate hurdle
Transit woes mount for Boston's beleaguered subway riders
Dems push Biden climate, health priorities toward Senate OK
pixel
S&P 500   4,145.19
DOW   32,803.47
QQQ   321.75
China July exports rise, with trade surplus at record-high
Demand for grocery delivery cools as food costs rise
Musk says Twitter deal could move ahead with 'bot' info
Shift in war's front seen as ships cleared to leave Ukraine
Dems' climate, energy, tax bill clears initial Senate hurdle
Transit woes mount for Boston's beleaguered subway riders
Dems push Biden climate, health priorities toward Senate OK
pixel
S&P 500   4,145.19
DOW   32,803.47
QQQ   321.75
China July exports rise, with trade surplus at record-high
Demand for grocery delivery cools as food costs rise
Musk says Twitter deal could move ahead with 'bot' info
Shift in war's front seen as ships cleared to leave Ukraine
Dems' climate, energy, tax bill clears initial Senate hurdle
Transit woes mount for Boston's beleaguered subway riders
Dems push Biden climate, health priorities toward Senate OK
pixel
NASDAQ:OPGN

OpGen (OPGN) Stock Forecast, Price & News

$0.62
0.00 (0.00%)
(As of 08/5/2022 12:00 AM ET)
Add
Compare
Today's Range
$0.59
$0.64
50-Day Range
$0.49
$0.69
52-Week Range
$0.31
$3.72
Volume
560,323 shs
Average Volume
345,394 shs
Market Capitalization
$28.87 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$2.13

OpGen MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.67 Rating Score
Upside/​Downside
242.7% Upside
$2.13 Price Target
Short Interest
Healthy
1.92% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.65mentions of OpGen in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.54) to ($0.41) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.29 out of 5 stars

Medical Sector

347th out of 1,283 stocks

Medical Laboratories Industry

11th out of 30 stocks

OpGen logo

About OpGen (NASDAQ:OPGN) Stock

OpGen, Inc., a precision medicine company, engages in developing and commercializing molecular microbiology solutions in the United States and internationally. Its product portfolio includes Acuitas AMR Gene Panel, an in vitro diagnostic (IVD) test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen, as well as Curetis CE-IVD-marked polymerase chain reaction-based SARS-CoV-2 test kits. The company's products also comprise ARES Technology Platform, including ARES reference database on antimicrobial resistance using next generation sequencing technology and artificial intelligence powered bioinformatics solutions for antibiotic response prediction; and Unyvero Platform, an automated sample-to-answer molecular diagnostics platform that integrates automated sample preparation, analysis, and identification of disease relevant pathogens and antibiotic resistance markers. The company utilizes molecular diagnostics and informatics to help combat infectious diseases. It also helps clinicians with information about life threatening infections to enhance patient outcomes, and to decrease the spread of infections caused by multidrug-resistant microorganisms. OpGen, Inc. has a collaboration with the New York State Department of Health and ILÚM Health Solutions, LLC to develop a research program to detect, track, and manage antimicrobial-resistant infections at healthcare institutions. The company was incorporated in 2001 and is headquartered in Rockville, Maryland.

OpGen Stock Performance

OpGen stock opened at $0.62 on Friday. The stock has a market cap of $28.87 million, a P/E ratio of -0.73 and a beta of -0.37. The company has a current ratio of 1.76, a quick ratio of 1.69 and a debt-to-equity ratio of 0.23. The stock has a 50 day moving average of $0.56 and a 200-day moving average of $0.66. OpGen has a 52 week low of $0.31 and a 52 week high of $3.72.

OpGen (NASDAQ:OPGN - Get Rating) last released its earnings results on Thursday, May 12th. The medical research company reported ($0.15) EPS for the quarter, beating the consensus estimate of ($0.16) by $0.01. The company had revenue of $0.47 million during the quarter, compared to analysts' expectations of $1.05 million. OpGen had a negative return on equity of 72.67% and a negative net margin of 680.36%. On average, analysts expect that OpGen will post -0.54 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on OPGN shares. Alliance Global Partners downgraded shares of OpGen to a "neutral" rating in a research report on Tuesday, July 19th. StockNews.com started coverage on shares of OpGen in a research report on Friday. They issued a "sell" rating for the company. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $3.00 price objective on shares of OpGen in a research report on Friday, June 10th.

Receive OPGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for OpGen and its competitors with MarketBeat's FREE daily newsletter.

OPGN Stock News Headlines

StockNews.com Initiates Coverage on OpGen (NASDAQ:OPGN)
27 U.S. Cities Where Stocks Yield 26% a Year
What’s the highest-yielding stock you’ve ever owned? The dividends for these stocks have risen so fast over the years that they’re now yielding us an average of 26%! When you start getting paid 26% on your money, your financial problems tend to pretty much evaporate. pixel
27 U.S. Cities Where Stocks Yield 26% a Year
What’s the highest-yielding stock you’ve ever owned? The dividends for these stocks have risen so fast over the years that they’re now yielding us an average of 26%! When you start getting paid 26% on your money, your financial problems tend to pretty much evaporate. pixel
OpGen (NASDAQ:OPGN) Now Covered by Analysts at StockNews.com
OpGen (NASDAQ:OPGN) Now Covered by StockNews.com
See More Headlines

Receive OPGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for OpGen and its competitors with MarketBeat's FREE daily newsletter.

OPGN Company Calendar

Last Earnings
5/12/2022
Today
8/07/2022
Next Earnings (Confirmed)
8/11/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Medical laboratories
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:OPGN
Employees
91
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$2.13
High Stock Price Forecast
$3.00
Low Stock Price Forecast
$1.25
Forecasted Upside/Downside
+242.7%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
3 Analysts

Profitability

Net Income
$-34,810,000.00
Net Margins
-680.36%
Pretax Margin
-676.84%

Debt

Sales & Book Value

Annual Sales
$4.31 million
Book Value
$1.06 per share

Miscellaneous

Free Float
45,971,000
Market Cap
$28.87 million
Optionable
Not Optionable
Beta
-0.37

Key Executives

  • Dr. Oliver Schacht Ph.D. (Age 51)
    CEO, Pres & Director
    Comp: $600.2k
  • Mr. Johannes Bacher (Age 53)
    Chief Operating Officer
    Comp: $396.52k
  • Mr. Albert Weber (Age 59)
    CFO & Corp. Sec.
  • Mr. Vadim Sapiro (Age 51)
    Chief Information Officer
  • Mr. Michael Farmer
    VP of Marketing
  • Ms. Faranak Atrzadeh
    Chief Marketing & Scientific Affairs Officer
  • Dr. G. Terrance Walker Ph.D. (Age 63)
    Sr. VP of R&D
  • Mr. Derek Joesting
    Sr. VP of US Sales
  • Dr. Arne Materna
    MD & CEO of Ares Genetics GmbH













OPGN Stock - Frequently Asked Questions

Should I buy or sell OpGen stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for OpGen in the last year. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" OpGen stock.
View analyst ratings for OpGen
or view top-rated stocks.

What is OpGen's stock price forecast for 2022?

3 analysts have issued 12-month target prices for OpGen's stock. Their OPGN stock forecasts range from $1.25 to $3.00. On average, they anticipate OpGen's share price to reach $2.13 in the next twelve months. This suggests a possible upside of 242.7% from the stock's current price.
View analysts' price targets for OpGen
or view top-rated stocks among Wall Street analysts.

How has OpGen's stock performed in 2022?

OpGen's stock was trading at $1.00 at the beginning of the year. Since then, OPGN shares have decreased by 38.0% and is now trading at $0.62.
View the best growth stocks for 2022 here
.

When is OpGen's next earnings date?

OpGen is scheduled to release its next quarterly earnings announcement on Thursday, August 11th 2022.
View our earnings forecast for OpGen
.

How can I listen to OpGen's earnings call?

OpGen will be holding an earnings conference call on Thursday, August 11th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link or dial in at 412-317-6671 with passcode "13730742".

How were OpGen's earnings last quarter?

OpGen, Inc. (NASDAQ:OPGN) posted its quarterly earnings results on Thursday, May, 12th. The medical research company reported ($0.15) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.16) by $0.01. The medical research company had revenue of $0.47 million for the quarter, compared to analyst estimates of $1.05 million. OpGen had a negative net margin of 680.36% and a negative trailing twelve-month return on equity of 72.67%.

When did OpGen's stock split? How did OpGen's stock split work?

OpGen shares reverse split before market open on Friday, January 19th 2018. The 1-25 reverse split was announced on Wednesday, January 17th 2018. The number of shares owned by shareholders was adjusted after the market closes on Thursday, January 18th 2018. An investor that had 100 shares of OpGen stock prior to the reverse split would have 4 shares after the split.

What guidance has OpGen issued on next quarter's earnings?

OpGen issued an update on its second quarter 2022 earnings guidance on Friday, July, 29th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $1.00 million-$1.00 million, compared to the consensus revenue estimate of $950.00K.

What other stocks do shareholders of OpGen own?

When did OpGen IPO?

(OPGN) raised $17 million in an initial public offering (IPO) on Tuesday, May 5th 2015. The company issued 2,900,000 shares at $5.50-$6.50 per share. Maxim Group acted as the underwriter for the IPO and National Securities was co-manager.

What is OpGen's stock symbol?

OpGen trades on the NASDAQ under the ticker symbol "OPGN."

How do I buy shares of OpGen?

Shares of OPGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is OpGen's stock price today?

One share of OPGN stock can currently be purchased for approximately $0.62.

How much money does OpGen make?

OpGen (NASDAQ:OPGN) has a market capitalization of $28.87 million and generates $4.31 million in revenue each year. The medical research company earns $-34,810,000.00 in net income (profit) each year or ($0.85) on an earnings per share basis.

How many employees does OpGen have?

OpGen employs 91 workers across the globe.

How can I contact OpGen?

OpGen's mailing address is 708 QUINCE ORCHARD ROAD SUITE 205, GAITHERSBURG MD, 20878. The official website for OpGen is www.opgen.com. The medical research company can be reached via phone at (240) 813-1260, via email at investorrelations@opgen.com, or via fax at 301-869-9684.

This page (NASDAQ:OPGN) was last updated on 8/7/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.